Surf Bio has acquired Halozyme, Inc., a biopharmaceutical company known for its innovative drug delivery solutions, for $400.0 million. This corporate acquisition sees Surf Bio taking full ownership of Halozyme, integrating its proprietary technologies and established partnerships into its operations.
Halozyme specializes in developing disruptive solutions to improve patient experiences and outcomes for various therapies. Its flagship ENHANZE® technology, based on the proprietary enzyme rHuPH20, significantly reduces the time required for certain injected treatments, transforming hours-long procedures into minutes. This commercially validated solution has positively impacted over 400,000 patient lives through five commercialized products across more than 100 global markets. Halozyme licenses its ENHANZE® technology to leading pharmaceutical and biotechnology companies, including Roche, Pfizer, and Janssen, generating revenue through milestones and royalties as partners develop and commercialize products.
The acquisition is a strategic move for Surf Bio, providing immediate access to Halozyme's advanced drug delivery platform and its extensive network of biopharmaceutical collaborations. This integration is expected to enhance Surf Bio's capabilities in drug development and commercialization, leveraging Halozyme's proven expertise in improving therapeutic administration and patient convenience. The deal underscores Surf Bio's commitment to expanding its footprint in the biopharmaceutical sector with a focus on innovative solutions that address patient needs.
Through this acquisition, Surf Bio aims to capitalize on the synergies between the two entities, potentially accelerating the development of new therapies and expanding the application of the ENHANZE® technology. The combined entity is poised to further advance solutions that improve drug delivery and patient outcomes globally, building on Halozyme's foundation of innovation and partnership.